Sector News

Novartis cozies up to Silicon Valley with new lab

October 10, 2018
Life sciences

Novartis is set to open innovation labs around the world to connect with tech companies. The labs, the first of which has opened in San Francisco, will serve as a bridge between companies developing R&D-enhancing technologies and the broader Novartis business.

Switzerland’s Novartis hit upon the idea after identifying a gap in the technology development and adoption process. Tech companies, from Alphabet, Amazon and Apple down to startups, are working on products and services that could improve R&D and other parts of the biopharma industry. But these companies can be disconnected from organizations that will use their technologies, depriving them of input that could ensure they meet the needs of potential customers such as Novartis.

“Healthcare is not an easy space to crack,” Novartis’ chief digital officer Bertrand Bodson toldBloomberg.

Novartis unveiled its fix for the problem, dubbed Novartis Biome, in a blog post and video Monday. The big unveil was preceded by months of work. According to his LinkedIn profile, Mohanad Fors has held the title of head of Novartis Biome since November. And members of the Biome team had a stand at TechCrunch Disrupt SF last month.

The team used the TechCrunch event to unveil the winners of its first HealthX World Series challenge. The challenge tasked developers with creating digital technologies that improve the monitoring, management and prediction of heart failure.

One of the winners of the challenge, Veta Health, is among the first set of companies to work with Biome. Novartis is also working with Mekonos, a cell and gene therapy startup that wants to replace viral vectors with a “silicon-based nano-robotic system.”

Novartis will provide work space, share data and assign mentors to the companies it works with through Biome. These mentors will be people who have seen an opportunity to use a nascent technology at Novartis, putting them in a good position to help their startups design and run validation studies. Novartis may invest in the startups after seeing validation results.

The initiative, which is set to expand beyond San Francisco to cities around the world, provides more evidence of the direction Novartis is heading under Vas Narasimhan. Since taking over as CEO, Narasimhan has put data and the technology to manage it at the heart of his vision for how Novartis will evolve in the years to come.

By: Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).